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Background: A lipid emulsion composed of soybean oil (long-chain triglycerides, LCT), medium-chain triglycerides
(MCT) and n-3 poly-unsaturated fatty acids (PUFAs) was evaluated for immune-modulation efficacy, safety, and
tolerance in patients undergoing major surgery for gastric and colorectal cancer.
Methods: In a prospective, randomized, double-blind study, 99 patients with gastric and colorectal cancer receiving
elective surgery were recruited and randomly assigned to either the study group, receiving the n-3 PUFAs enriched
intravenous fat emulsion (IVFE), or the control group, receiving a lipid emulsion comprised of soybean oil and MCTs
(0.8 – 1.5 g · kg−1 · day−1) as part of total parenteral nutrition (TPN) regimen from surgery (day −1) up to post-operative
day 7. Safety and efficacy parameters were assessed on day −1 and post-operative visits on day 1, 3, and 7. Adverse
events were documented daily and compared between the groups.
Results: Pro-inflammatory markers, laboratory parameters, and adverse events did not differ prominently between
the 2 groups, with the exception of net changes (day 7 minus day −1) of free fatty acids (FFAs), triglyceride, and
high-density lipoprotein (HDL). Net decrease of FFAs was remarkably higher in the study group, while the net
increase of triglyceride and decrease of HDL was significantly lower.
Conclusions: The n-3 PUFA-enriched IVFE showed improvements in lipid metabolism. In respect of efficacy, safety
and tolerance both IVFE were comparable. In patients with severe stress, there is an inflammation-attenuating effect
of n-3 PUFAs. Further, adequately powered clinical trials will be necessary to address this question in postsurgical GI
cancer patients.
Trial registration: US ClinicalTrials.gov NCT00798447.
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Surgical injury is followed by profound changes in endo-
crine metabolic function and various host defense mech-
anisms leading to catabolism, immunosuppression, ileus,
impaired pulmonary function, and hypoxemia. Nutritional
intervention may substantially alter the immune function
with potential impact on the post-operative morbidity [1].
Patients with gastrointestinal cancer undergoing major
surgery are usually malnourished before surgery and will
sustain a worsening of this status because of prohibited
enteral nutrition after digestive surgery as well as surgery
induced stress metabolism.
Malnutrition due to preoperative poor gastrointestinal
function and/or postoperative stress metabolism leads to
an increase in morbidity and mortality by mechanisms
impairing patients’ immune system. Analyzing the nutri-
tional status adequately allows implementation of appropri-
ate nutrition therapy. The nutritional regimen will usually
be composed to provide the basic requirements of patients
and thus should contain amino acids, glucose and lipids as
well as micronutrients and electrolytes. In addition to their
role in providing energy, omega 3 polyunsaturated fatty
acids (n-3 PUFAs) have additional features, such as the
modulation of the metabolic and inflammatory responses
that are of benefit to malnourished patients receiving sur-
gery. N-3 PUFAs are preferentially incorporated into cell
membrane phospholipids, influence secondary messenger
synthesis and modulate the expression of certain adhesion
molecules at the surface of endothelial cells, monocytes
and lymphocytes [2,3]. They have been shown to influence
cell membrane fluidity and permeability and to modify
the cell membrane receptors and enzymes activity [4,5].
N-3 PUFAs compete with arachidonic acid to produce
prostaglandins, leukotrienes, and thromboxanes with less
inflammatory and less thrombotic properties [6-8]. It thus
appears that n-3 PUFAs may regulate pro- and anti-
inflammatory cytokine gene expression and might be a
promising therapy in conditions characterized by inappro-
priate pro-inflammatory activity [9]. Studies undertaken
with n-3 PUFAs containing parenteral lipid emulsions in
patients undergoing major abdominal surgery [10,11], in
patients undergoing surgery for aortic aneurism repair
[12], and in patients with acute respiratory distress syn-
drome (ARDS) [13,14], have proven clinically to reduce
length of post-operative hospital stay, frequency of post-
operative complications, as well as to lower the levels of
pro-inflammatory factors such as leukotriene B4 (LTB4)
[14] and Interleukin 6 (IL-6) [15].
The aforementioned data and scientific background
suggest that the application of lipid emulsions containing
n-3 PUFAs before and after surgery may show beneficial
effects. Herein, we had conducted a phase III, prospective,
randomized, double-blind, bi-centric, active-controlled,
parallel group study to evaluate the efficacy and safety ofthe n-3 PUFAs containing lipid emulsion in patients
undergoing major surgery for gastric and colorectal
cancer.
Methods
The protocol was approved by the local ethics committees
((R9746) IRB-951008) and was carried out in accordance
with the Declaration of Helsinki of 1975 as revised in 1996.
Written informed consents of patients were obtained
before the study was conducted. The study was registered
at clinicaltrials.gov under the identification code ID:
NCT00798447 and the trial name: Efficacy and Safety
of a PN Regimen Containing n-3 Fatty Acid in Patients
Considered after GI Surgery.
In this prospective randomized, double-blind study,
patients ≧ 18 years of age in Kaohsiung Medical University
Hospital (KMUH) and National Taiwan University Hos-
pital (NTUH) following elective radical surgery for gastric
and colorectal cancer in open method from January 2009
to October 2010 were screened for eligibility in our study.
The following patients were excluded: Those with severe
hypoalbuminemia (albumin <2.5 g/dL), diabetes mellitus,
or hyperlipidemia (fasting serum triglyceride >250 mg/dL),
those who were overweight (body mass index >30 kg/m2),
had drug abuse or chronic alcoholism, liver disease (total
bilirubin >2 mg/dL), renal disease (creatinine >2 mg/dL or
needing hemodialysis), alternations of coagulation (throm-
bocytes < 150 × 103/uL; international normalized ratio > 1.5;
partial thromboplastin time > 40 sec), heart failure, life-
threatening disease, those who were pregnant or lactating,
those who received chemotherapy within 14 days before
the start of the trial, had already accepted enteral nutri-
tion, or participated in another clinical study with an
investigational drug or an investigational medical device
within a month prior to the start or during the study, and
those who were hypersensitive to fish, egg, soy, or peanut
protein. Before initiation of the study, a randomization
sequence was computer-generated (GraphPad statistical
software, GraphPad, USA) with two blocks of 60 patients
each that was 1:1 allocated by an independent investigator
(JFC). The patients were therefore assigned to either the
study group or the control group and received the blinded
study medication in identical appearance according to the
randomization sequence by two investigators (CJM at
KMUH and JMW at NTUH). All the investigators and
staff, except for the independent investigator mentioned
above, were kept blind to the assignment till the end of
study. Based on the randomization sequence, emergency
envelops were provided to the study centers to break
blinding if reasonable suspicion of harm to the par-
ticipants due to the investigational lipid emulsion was
expressed. The emergency envelops were provided in
three sets, one of which was installed at the ward another
at the pharmacy of each respective hospital and the third
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AG, Germany.
A total caloric supplement of 20–35 kcal/kg ideal body
weight (BW)/day parenteral nutrition, including 1.2 g
amino acid/kg BW/day, 3–4 g glucose/kg BW/day, 0.8-
1.5 g lipid/kg BW/day and electrolyte, micro-element
and vitamin according to the nutritional status of subjects
and followed the standard procedure of the hospital, was
infused continuously daily for the day before surgery and
consecutive post-operative 7 days in an infusion time
ranged between 18–24 hours. The doses of nutritional
components were selected according to the European
Society for Parenteral and Enteral Nutrition (ESPEN)
guideline on parenteral nutrition for patients undergoing
surgery. According to the assignment of the patients, the
study group (MCT/LCT/n-3) received Lipoplus® 20% (B.
Braun, Melsungen AG, Germany) and the control group
(MCT/LCT) Lipofundin® MCT 20% (B. Braun, Melsungen
AG, Germany), as part of the parenteral nutrition regimen
provided to the subjects. The composition of each lipid
emulsion is shown in Table 1. Energy expenditure is calcu-
lated according to Harris-Benedict Equation, and one or
two bottles (usually one bottle) of lipid emulsion are
administered to meet requirement of 0.8-1.5 g lipid/kg
BW/day. The rest of calories needed are adjusted by
glucose. Lipoplus® 20% contains 12.6-26.0 mg/ml of n-3
PUFAs and provided amount of 0.8-1.5 g lipid/kg BW/day
is equivalent to 4–7.5 ml/kg BW/day. Approximately
80–140 mg/kg BW/day of n-3 PUFAs were provided in
the study group. Enteral nutrition was restricted to clear
liquid during 7 days postoperatively.
The primary objective was to evaluate the impact of n-





LCT (soybean oil), g/l 80 100
MCT, g/l 100 100
Fish oil, g/l 20 -
Egg phospholipids, g/l 12 12
Glycerol, g/l 25 25
Essential fatty acids
LA (n-6 PUFA), g/l 38-46 48-58
ALA (n-3 PUFA), g/l 4.0-8.8 5-11
EPA and DHA (n-3 PUFA) , g/l 8.6-17.2
n-6/n-3 fatty acid ratio 2.7:1 7-9:1
Total energy, kcal/l 1910 1910
pH 6.5-8.5 6.5-8.5
Osmolarity, mOsm/l 410 380
LCT: long-chain triglyceride; MCT: medium-chain triglyceride; LA: linoleic acid;
PUFA: polyunsaturated fatty acid; ALA: α-linoleic acid; EPA: eicosapentaenoic
acid; DHA: docosahexaenoic acid.Inflammatory markers used to assess inflammatory pro-
cesses include IL-6, C-reactive protein (CRP), tumor
necrosis factor-α (TNF-α) and procalcitonin (PCT). The
respective levels were measured together with metabolic
parameters on day −1, before and after surgery, and post-
operative days 1, 3 and 7 as well as at follow up. Follow up
was defined as 30 days after last treatment. Metabolic
efficacy was measured by free fatty acids (FFA), triglycer-
ides (TG), total cholesterol (TC), low-density lipoprotein
(LDL), high-density lipoprotein (HDL), glucose and insu-
lin. Metabolic efficacy was measured by the net changes
(day 7 minus day −1).
Safety was assessed by hepatological variables including
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), gamma-glutamyl transpeptidase (γGT), direct biliru-
bin and albumin, by hematological variables including
international normalized ratio (INR), partial thromboplastin
time (PTT), leukocyte-, platelet- and erythrocyte-count. All
the hepatological and hematological safety parameters were
measured on day −1, days 1, 3, and 7. Vital signs, fluid
input, clinical course, concomitant medication, concomi-
tant procedure, adverse events (AEs) and severe adverse
events (SAEs) were recorded daily between day −1 and day
7 before administration of parenteral nutrition. Last visit of
the patients was at discharge from hospital or 30 days after
last treatment whatever occurred first. Clinical outcomes
and AEs/SAEs were assessed until discharge of the patients
from hospital. AEs/SAEs were coded using the MedDRA
system (version 13.0, http://www.meddra.org) and summa-
rized descriptively by system organ class.
To derive a sample size (equal in both study arms), it
was required to specify the expected data regarding the
primary end-point, the statistical significance level and the
power. Based on published data about the influence of
enteral nutrition regimen containing n-3 PUFAs on IL-6
release in Asian population, [16] we had conducted a 2-
sided testing of independent means with the following
values of IL-6. Treatment group (9 days after surgery –
baseline) was 142 ± 118 pg/mL and control group (9 days
after surgery – baseline) was 220 ± 124 pg/mL. The stand-
ard statistical significance of 5% and 80% power of reject-
ing null hypothesis when alternative hypothesis was
corrected were chosen. The sample size calculation per-
forms with software program nQuery version 5.0 results
in 41 patients at least. Taking into a drop-out rate of 20%,
the sample size is 50 patients per study arm i.e. a total 100
patients in the study.
Results are compared using Mann–Whitney U test or
Kruskal-Wallis test for ordered categorical counts in
case of non-paired data. In case of paired data the
Wilcoxon rank-sum test or Friedman test is used. For
the comparison of dichotomous variables the Fisher’s
exact test is used. To variables of categorical character
with more than two categories the Pearson chi-square test
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test is used. Means are compared using the 2-sample test
and if appropriate using analysis of variance (ANOVA),
where appropriate linear regression is performed. Yet, for
all inferential analysis methods described above, the center
effect is not considered when comparing one treatment to
the other. Therefore, ANOVA incorporating center effect
and Cochran-Mantel-Haenszel test stratified by center are
applied to replace 2-sample t-test and Fisher’s exact test.
For efficacy analyses and part of the safety analyses (in-
cluding of laboratory data and vital sign data), in order to
consider the impact of baseline data on the endpoints,
analysis of covariance (ANOVA) was applied when com-
paring a treatment mean to another, with their respective
baseline as covariate. Baseline was defined as the data
obtained before first administration of treatment before
surgery. Endpoints were defined as net change of post-
treatment from baseline. Statistical analyses were con-
ducted with SPSS 18.0 (SPSS, Chicago, IL, USA).
Results
A total of 100 subjects were planned for enrollment in
order to gain 82 evaluable subjects, with 41 in each
treatment arm. Before the screening visit, a total of 128
patients diagnosed with gastric or colorectal cancer were
each given a screening number by the study nurse. How-
ever, in site NTUH, 27 pre-screened patients neither
signed the informed consent form nor had protocolized
screening activities performed by investigators, and thus
were excluded before the screening visit. The remaining
101 patients signed the informed consent form and had
screening visits. Two subjects in site KMUH were
screening failures. In the end, 99 patients who took at
least one dose of study treatment had safety evaluations
and comprised the safety population (51 in the study
group, 48 in the control group). Figure 1 shows the
disposition of subjects for the two treatment groups. A
total of 8 subjects were withdrawn prior to post-
operative day 1 and only received study medication on
the day before surgery (i.e. day −1). Aside from the 8
subjects mentioned above, 5 subjects were also with-
drawn from this trial and did not receive all scheduled
lipid emulsion infusions (Table 2). The remaining 85 pa-
tients who received treatment medications from day −1 to
day 7 and fulfilled all entry criteria were completers and
where therefore included in the per protocol population.
The demographic characteristics of all subjects are sum-
marized in Table 3. The groups were comparable with
respect to demographic data with no difference in fluid
input, concomitant medications, or concomitant proce-
dures between the test groups. The distribution of tumor
staging between test groups also seemed consistent.
All laboratory parameters were comparable in treat-
ment groups at baseline, and similar trends betweentreatment groups were observed throughout the study
period (Table 4). However, statistically significant differ-
ences between groups were detected in the net changes
of FFA, TG and HDL from day −1 to post-operative
visits. Patients in study group (i.e. MCT/LCT/n-3) showed
a significantly stronger reduction in net change of FFA
when compared with the control group (i.e. MCT/LCT)
from day −1 to day 7 (−0.201 mmol/L vs. -0.026 mmol/L,
p = 0.013). Moreover, patients from both groups had
increments in TG levels after surgery, but the increment
from day −1 to day 7 was less in the study group as
compared with the control group (20.98 mg/dl vs.
66.69 mg/dl, p = 0.0006). Lastly, both groups exhibited sta-
tistically significant differences in net change of HDL from
day −1 to day 3 (−0.85 mg/dl vs. -6.11 mg/dl, p = 0.0097)
and from day −1 to day 7 (−12.58 mg/dl vs. -17.36 mg/dl,
p = 0.0099), where HDL level reduction was less in the
study group. Despite the differences, the aforementioned
parameters were all within normal range.
Pro-inflammatory factors (IL-6, CRP, TNF-α, and PCT)
were comparable in the two groups, but no prominent
differences were observed (Table 5). Despite a higher level
of pro-inflammatory factors in the control group at each
visit time, the two treatment groups did not show any
statistically significant difference. The two groups demon-
strated consistent trends in pro-inflammatory factors levels
during the study period. The IL-6 level immediately
reached the peak after surgery and the CRP and the PCT
levels reached the peak on day 3 and day 1 respectively. All
three parameters gradually decreased afterwards and there
was no statistical difference on each day it was measured
between test groups. The level of TNF-α didn’t vary obvi-
ously and had no significant difference between two groups,
either (Figure 2).
The extent of exposure, in terms of days of 99 patients
exposed to lipid emulsion was 7.49 days for the study
group, and 7.17 days for the control group. Moreover,
both groups demonstrated median extent of exposing as
8 days. There was no significant difference in the extent
of exposure between treatment groups (p = 0.399).
A total of 6 patients experienced pre-treatment AEs, hav-
ing 2 (3.9%) vs. 4 (8.3%) of subjects in the study vs. control
group, respectively. No significant difference was observed
(p = 0.371). A total of 314 incidents of treatment-emergent
AEs had occurred in 88 (88.9%) subjects, with 47 (92.2%)
and 41 (85.4%) subjects in study and control group, respect-
ively (p = 0.243). The most reported AEs were injuries;
poisoning, procedural complications and general disorders
and administration site conditions were the second most
frequently occurring AEs (Table 6). There were no particu-
lar treatment group differences concerning the category
and incidence of treatment-emergent AEs.
Approximately 80% of AEs were related as mild in
intensity and nearly one-fifth of AEs were moderate.
a
The central venous catheter of one subject was removed on day 6; it was too late  
for starting parenteral nutrition on day 1 at the requested time.
b 
Subjects who completed all 8-day treatment.
Randomized population N = 99
(KMUH: 61; NTUH: 38)
Study group
(MCT/LCT/n-3) N = 51
Control Group
(MCT/LCT) N = 48
6 withdrawls:
1 severe adverse event
1 withdrew consent
1 violated entry criteria




1 severe adverse event
2 adverse events
3 withdrew consent





Figure 1 Diagram of randomization of patients with gastric or colorectal cancer to receive an n-3 fatty acid enriched parenteral lipid
emulsion or a control parenteral lipid emulsion (MCT/LCT).
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One of the SAEs occurred in a subject in the study group
with wound complication, septic shock and blood pres-
sure decreased. Another was a subject reported with sep-
tic shock in the control group. Both SAEs were observedTable 2 List of subjects who were excluded from per protoco
Treatment Reason for premature termination
Study group (MCT/LCT/n-3) Subject withdrew consent
Subject withdrew from the study due to w
Platelet at screening visit was 135 × 103/uL
Subject used incorrect treatment (used MC
Patient experienced life-threatening SAE
Central venous catheter was removed due
Too late for starting PN on day 1 at reques
Control group (LCT/MCT) AE: bilateral ankle pain
Subject withdrew consent
High fever, suspect central venous cathete
Subject withdrew consent
Acute bowel obstruction developed and p
diversion colostomy and staged surgery
Patient experienced life-threatening SAE
Subject withdrew consent
SAE: severe adverse event; AE: adverse event.on day 7 and caused the withdrawal of both subjects from
the study. AST was the only AE which was possibly
related to trial medication. This AE was reported as mild
in intensity and no action was taken regarding this epi-
sode. No death was encountered in this study.l population
Treatment duration
1 day
ithout pathological evidence of colon cancer 5 days
, < 150 × 103/uL 8 days
T/LCT) 1 day
7 days
to infection 6 days
ted time 1 day
1 day
1 day
r infection 3 days
1 day
atient underwent 1 day
7 days
1 day
Table 3 Demographic data in our studied patients
Study group (N = 51) Control Group (N = 48) P
Sex
Male/Female 29/22 27/21 0.960
Age (years) 61.55 ± 9.78 62.85 ± 10.12 0.530
Body weights (kg) 59.82 ± 11.04 61.55 ± 10.95 0.415
BMI (kg/m2) 23.45 ± 3.44 23.91 ± 3.79 0.501
Tumor staging – Gastric cancer Total
N 14 12 26
UICC Stage I 4 (28.6%) 1 (8.3%) 5 (19.2%)
Stage II 3 (21.4%) 4 (33.3%) 7 (26.9%)
Stage III 4 (28.6%) 2 (16.7%) 6 (23.1%)
Stage IV 3 (21.4%) 5 (41.7%) 8 (30.8%)
Tumor staging – Colorectal cancer
N 36 37 73
UICC Stage I 3 (8.3%) 3 (8.1%) 6 (8.2%)
Stage II 15 (41.7%) 12 (32.4%) 27 (37.0%)
Stage III 14 (38.9%) 15 (40.5%) 29 (39.7%)
Stage IV 4 (11.1%) 7 (18.9%) 11 (15.1%)
UICC: union of international cancer control.
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Patients considered for major surgery for gastric and
colorectal cancer are usually malnourished before surgery,
and very likely to undergo a worsening of this status,
because of surgery induced stress metabolism leading
to an increase in morbidity and mortality. Nonetheless,
nutritional intervention may substantially alter the nutri-
tional status as well as the immune function with potential
impact on the post-operative course. Lipid emulsions
containing n-3 PUFAs, namely eicosapentaenoic acid
(EPA) and docosahexanoic acid (DHA), are introduced
into the international market of PN. Next to provision
of energy, studies have demonstrated that these n-3
PUFAs may regulate pro- and anti-inflammatory cytokine
gene expression and compete with AA for the enzymes
involved in eicosanoid metabolism and thus might rep-
resent a promising therapy in conditions characterized
by inappropriate pro-inflammatory activity [9].
IL-6, CRP and TNF-α are common and sensitive but
non-specific markers of inflammatory processes and
increased concentrations are measured after trauma and in
sepsis. Thus, they are chosen to evaluate immune modulat-
ing effects of n-3 PUFAs. To complement the inflammatory
assessment, PCT as an early and highly sensitive marker of
inflammation of bacteriological origin is included into the
analysis. PCT is also considered to serve as decision marker
for any needed antibiotic treatment.
In fact, there is clinical evidence showing anti-inflam-
matory and immunomodulatory effects of n-3 PUFAs
on rheumatoid arthritis [17-19], lupus [20,21], andinflammatory bowel disease [22-24], which are hyperin-
flammatory autoimmune diseases. Several studies have
demonstrated that n-3 fatty acids can modulate the im-
mune response as determined by an improved eicosanoids
profile [15,16,25,26]. In surgical patients, the earlier study
of Wachtler et al. could show significant attenuating effects
of n-3 fatty acids on IL-6 levels in patients undergoing
elective major surgery [15]. Also in the study by Chen et al.
[16], on which the case number calculation for our current
trial was performed, lower postoperative IL-6 levels of
patients undergoing major gastrointestinal surgery were
reported in the n-3 fatty acid group.
The levels of IL-6, TNF-α, CRP, and PCT in study
group are all significantly lower than control group at
each visit time and therefore, n-3 PUFAs have a trend to
reduce pro-inflammatory factors. However, consistent
with our previously published study, [11] our results
show that n-3 PUFAs containing lipid emulsion as part
of PN does not significantly influence levels of pro-
inflammatory factors, including IL-6, TNF-α, CRP, and
PCT, or clinical outcomes in patients, undergoing elective
surgery. Noteworthy, in the study by Chen et al., adminis-
tration of enteral immunonutrition in patients with gastric
carcinoma undergoing major surgery, the IL-6 values on
the day of surgery, directly after surgery, are reported
above/on average 270–299 pg/ml. On post-operative day
1 the IL-6 values are even as high as 584 pg/ml (mean).
After 9 days, the values of IL-6 are still high (mean
411 pg/ml in the immunonutrition group, mean 519 pg/
ml in the control group). Thus, the inflammatory response
Table 4 Various laboratory data before and after operation between the two studied groups
Study group (N = 44) Control group (N = 41) Difference1,2 [95% C.I.] P
FFA (mmol/L)
Day −1 0.60 ± 0.35 0.65 ± 0.41 −0.044 [−0.196; 0.108] 0.566
Day 7 – Day −1 −0.20 ± 0.38 −0.03 ± 0.62 −0.195 [−0.347; −0.042] 0.013
TG (mg/dL)
Day −1 97.45 ± 41.12 95.06 ± 38.72 2.263 [−13.714; 18.239] 0.779
Day 7 – Day −1 20.98 ± 44.85 66.69 ± 68.85 −44.109 [−68.583; −19.634] <0.001
Cholesterol (mg/mL)
Day −1 179.22 ± 34.27 177.77 ± 39.04 1.188 [−13.225; 15.600] 0.870
Day 7 – Day −1 −42.61 ± 32.00 −40.71 ± 34.86 −2.001 [−13.549; 9.546] 0.731
LDL (mg/mL)
Day −1 110.99 ± 23.93 109.40 ± 36.00 1.660 [−10.504; 13.823] 0.787
Day 7 – Day −1 −28.70 ± 25.76 −27.41 ± 30.50 −1.350 [−11.281; 8.581] 0.788
HDL (mg/mL)
Day −1 37.85 ± 12.62 40.57 ± 14.87 −2.889 [−8.031; 2.254] 0.268
Day 7 – Day −1 −12.58 ± 8.70 −17.36 ± 10.01 3.226 [0.796; 5.656] 0.010
Insulin (mU/L)
Day −1 14.14 ± 14.96 21.80 ± 26.50 −7.547 [−16.107; 1.013] 0.083
Day 7 – Day −1 22.44 ± 24.68 9.80 ± 29.44 8.080 [−1.870; 18.029] 0.110
Glucose (mg/dL)
Day −1 133.31 ± 57.80 128.92 ± 52.68 4.840 [−16.791; 26.472] 0.658
Day 7 – Day −1 20.00 ± 47.80 29.91 ± 76.32 −6.656 [−30.295; 16.983] 0.577
ALT (U/L)
Day −1 18.65 ± 7.65 18.73 ± 12.16 −0.010 [−3.976; 3.956] 0.996
Day 7 – Day −1 25.35 ± 33.30 38.48 ± 43.24 −11.141 [−26.835; 4.552] 0.162
AST (U/L)
Day −1 23.77 ± 11.75 23.46 ± 11.80 0.325 [−4.394; 5.044] 0.892
Day 7 – Day −1 18.22 ± 34.51 24.62 ± 34.26 −4.523 [−18.384; 9.337] 0.518
γGT (U/L)
Day −1 21.88 ± 18.64 28.10 ± 47.67 −5.943 [−20.257; 8.371] 0.412
Day 7 – Day −1 78.27 ± 71.93 118.24 ± 112.41 −36.052 [−73.770; 1.667] 0.061
Albumin (g/dL)
Day −1 3.98 ± 0.47 4.01 ± 0.46 −0.035 [−0.194; 0.124] 0.662
Day 7 – Day −1 −0.42 ± 0.38 −0.51 ± 0.39 0.099 [−0.038; 0.236] 0.153
Bilirubin (mg/dL)
Day −1 0.15 ± 0.10 0.15 ± 0.08 0.002 [−0.034; 0.037] 0.929
Day 7 – Day −1 0.04 ± 0.26 0.09 ± 0.33 −0.052 [−0.171; 0.067] 0.389
Leukocyte (103/μL)
Day −1 5.91 ± 2.52 8.00 ± 12.85 −2.121 [−5.764; 1.522] 0.251
Day 7 – Day −1 28.41 ± 174.51 0.67 ± 14.01 23.872 [−31.335; 79.079] 0.392
FFA: free fatty acid; TG: triglyceride; LDL: low density lipoprotein; HDL: high density lipoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase;
γGT; gamma-glutamyl transpeptidase.
1Difference = [study group] - [control group].
2ANOVA incorporating center effect and their respective baseline as covariate; Difference and 95% C.I. was based on the LS-mean.
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Table 5 Various inflammatory factors before and after operation between the two studied groups
Study group (N = 44) control group (N = 41) Difference1,2 [95% C.I.] P
IL-6 (pg/mL)
Day −1 7.13 ± 19.22 21.16 ± 59.75 −13.724 [−32.496; 5.048] 0.150
Before surgery 11.78 ± 21.30 26.01 ± 52.29 −13.793 [−30.417; 2.824] 0.103
After surgery 126.56 ± 103.68 133.17 ± 109.18 −8.867 [−55.025; 37.291] 0.703
Day 1 99.40 ± 88.12 99.88 ± 97.50 −0.958 [−41.005; 39.089] 0.962
Day 3 35.72 ± 57.33 41.22 ± 63.48 −5.808 [−31.878; 20.262] 0.659
Day 7 23.58 ± 45.25 26.44 ± 53.61 −2.741 [−24.202; 18.719] 0.800
Follow up3 16.25 ± 19.46 22.15 ± 47.82 −5.810 [−21.446; 9.826] 0.462
Day 7 – Day −1 16.45 ± 28.31 5.27 ± 53.00 6.648 [−10.876; 24.172] 0.453
CRP (mg/dL)
Day −1 0.96 ± 1.80 2.04 ± 5.65 −1.069 [−2.857; 0.720] 0.238
Before surgery 1.13 ± 1.79 1.75 ± 3.91 −0.615 [−1.919; 0.688] 0.350
After surgery 1.52 ± 1.70 1.94 ± 3.49 −0.405 [−1.576; 0.765] 0.493
Day 1 8.31 ± 4.68 9.17 ± 4.80 −0.837 [−2.877; 1.202] 0.416
Day 3 10.20 ± 5.93 12.24 ± 7.52 −2.043 [−4.792; 0.885] 0.169
Day 7 4.92 ± 4.60 4.95 ± 5.12 −0.040 [−2.152; 2.072] 0.970
Follow up3 3.88 ± 4.72 5.23 ± 6.83 −1.304 [−3.804; 1.196] 0.303
Day 7 – Day −1 3.95 ± 4.89 3.01 ± 7.11 −0.004 [−2.155; 2.148] 0.997
TNF-α (pg/mL)
Day −1 2.00 ± 2.07 3.38 ± 6.59 −1.395 [−3.474; 0.685] 0.186
Before surgery 2.01 ± 1.09 3.17 ± 6.71 −1.176 [−3.224; 0.872] 0.257
After surgery 1.60 ± 1.43 3.05 ± 5.23 −1.475 [−3.096; 0.147] 0.074
Day 1 1.72 ± 1.67 2.88 ± 4.01 −1.174 [−2.485; 0.137] 0.079
Day 3 2.12 ± 2.24 3.33 ± 4.14 −1.237 [−2.653; 0.180] 0.086
Day 7 2.55 ± 2.30 3.70 ± 5.83 −1.169 [−3.061; 0.724] 0.223
Follow up3 2.42 ± 2.09 3.83 ± 5.44 −1.424 [−3.182; 0.334] 0.111
Day 7 – Day −1 0.55 ± 1.38 0.38 ± 1.63 0.002 [−0.609; 0.612] 0.995
PCT (ng/mL)
Day −1 0.06 ± 0.03 0.15 ± 0.37 −0.085 [−0.197; 0.027] 0.133
Before surgery 0.13 ± 0.15 0.16 ± 0.25 −0.029 [−0.118; 0.060] 0.518
After surgery 0.29 ± 0.31 0.32 ± 0.31 −0.029 [−0.163; 0.105] 0.671
Day 1 0.65 ± 0.82 0.80 ± 1.29 −0.148 [−0.612; 0.316] 0.528
Day 3 0.29 ± 0.29 0.41 ± 0.60 −0.125 [−0.325; 0.075] 0.216
Day 7 0.14 ± 0.15 0.24 ± 0.48 −0.097 [−0.249; 0.056] 0.211
Follow up3 0.12 ± 0.09 0.68 ± 1.88 −0.557 [−1.120; 0.006] 0.053
Day 7 – Day −1 0.08 ± 0.15 0.09 ± 0.62 −0.101 [−0.256; 0.055] 0.202
CRP: C-reactive protein; TNF-α: tumor necrosis factor-α; PCT: procalcitonin.
1Difference = [study group] - [control group].
2ANOVA incorporating center effect and their respective baseline as covariate; Difference and 95% C.I. was based on the LS-mean.
3Follow up was defined as 30 days after last treatment.
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http://www.nutritionj.com/content/14/1/9as judged by the IL-6 values seem to completely different
in the study by Chen et al. that IL-6 being 5 times higher
than in the current study. This may be explained by the
use of minimal invasive surgery in our study compared to
major surgical interventions in the previous one. Again,
PCT, as an early highly sensitive marker of inflammationof bacterial origin, elevated slightly in both groups in
conjunction with other inflammatory parameters also
indicates that the inflammatory response in our patients is
mild. As we expected a stronger inflammatory response,
and calculated the case number accordingly, the effect of





































































































































































Figure 2 Distribution of mean (SD) during the study period. (a) IL-6, (b) CRP, (c) TNF-α, (d) PCT. *Follow up was defined as 30 days after
last treatment.
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Table 6 Number (%) of treatment-emergent AEs with incidence > 5% by body system – safety population
System organ class Study group (N = 51) Control group (N = 48) Total (N = 99)
Gastrointestinal disorders Abdominal distension 3 (5.9%) 4 (8.3%) 7 (7.1%)
Nausea 4 (7.8%) 1 (2.1%) 5 (5.1%)
Vomiting 4 (7.8%) 1 (2.1%) 5 (5.1%)
General disorders and administration site conditions Pyrexia 24 (47.1%) 28 (58.3%) 52 (52.5%)
Infections and infestations Wound infection 3 (5.9%) 1 (2.1%) 4 (4.0%)
Injury, poisoning, and procedural complications Wound complication 40 (78.4%) 33 (68.8%) 73 (73.7%)
Investigations ALT increased 6 (11.8%) 6 (12.5%) 12 (12.1%)
AST increased 5 (9.8%) 6 (12.5%) 11 (11.1%)
CRP increased 5 (9.8%) 9 (18.8%) 14 (14.1%)
γGT increased 10 (19.6%) 11 (22.9%) 21 (21.2%)
White blood count increased 2 (3.9%) 7 (14.6%) 9 (9.1%)
Metabolism and nutrition disorders Hypoalbuminemia 5 (9.8%) 2 (4.2%) 7 (7.1)
ALT: alanine aminotranferase; AST: aspartate aminotranferase; CRP: C-reactive protein; γGT: gamma-glutamyltransferase.
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response are only mild.
Surgical trauma induces a catabolic response with
hypercatabolism and impaired lipid tolerance [27,28].
Hepatic triglyceride synthesis is related to the availability
of carbohydrate and fatty acid substrates [29]. As a
result, patients receiving postoperative PN may present
hyperlipidemia. In this study, the postoperative levels of
TG are elevated in both groups; however, the increase is
moderate and remains within normal ranges. The clear-
ance of FFA and TG in the study group is better than in
the control group, and elimination is adequate without
hypertriglyceridemia. Furthermore, decrease of HDL is
also less in the study group compared to the control.
However, metabolism of lipoprotein is complex and many
factors may influence the residence time. Although results
from Annuzzi et al. [30] demonstrates that administration
of n-3 PUFAs is associated with favorable lipoprotein
profile, it is a surveillance of lipoprotein and dietary n-
3 PUFAs but it is difficult to conclude that short time
of n-3 PUFAs infusion is also associated with a better
cholesterol profile.
Except for FFA, TG and HDL, laboratory parameters
regarding hepatological safety, hematological safety, lipid
and glucose metabolism as well as AEs are comparable
in both treatment groups. There is a trend in increased
level of AST, ALT and γGT as well as a trend in increased
level of corresponding FFA and TG. Increased FFA and
TG in blood, i.e. hyperlipidemia, may theoretically increase
fat storage in the liver, cause inflammation in the liver and
eventually result non-alcoholic fatty liver disease (NAFLD).
It is an observation within a short period window, though
this may explain the association of lipid profile and ele-
vated liver enzymes. The only AE which is possibly
treatment-related is a mild AST elevation. It is well known
that TPN may alter liver function tests after days ofadministration, and accordingly elevated AST and ALT
without a change in serum total bilirubin levels. The
mechanisms underlying such abnormalities are not fully
understood, although they may partially result from the
lack of gastrointestinal stimulation by enteral nutrition.
Two subjects, one in each treatment group, were docu-
mented with life-threatening SAE of septic shock, and the
study treatment was interfered regarding these episodes.
However, both SAEs were unrelated to study medication
and no death was recorded.
This study has limitations. First of all, the patients
selected are those who received elective surgery for
gastrointestinal cancers, instead of critically ill patients
with surgery for inflammatory or infectious diseases, such
as inflammatory bowel disease, peritonitis or necrotizing
pancreatitis and so on. The expected immunomodulatory
effects may be masked. Secondly, it is a treatment in a short
time, and only relative changes of several biomarkers can
be observed. Finally, our current study might not have been
sufficiently powered to draw significant conclusions, and
the detection of significant effects in surgical patients under
contemporary conditions (i.e. using minimal invasive sur-
gery) might require further and larger clinical trials.
Conclusions
Both lipid emulsions exerted a comparable effect on the
efficacy parameters chosen and n-3 PUFAs had limited
immunomodulation in normal subjects undergoing elect-
ive surgery for gastric and colorectal cancers. Despite
being a small-population study with some limitations
mentioned above, n-3 PUFAs may support better lipid
elimination; less development of hyperlipidemia and n-3
PUFAs containing lipid emulsion is safe and well toler-
ated as a standard lipid emulsion in the immediate
postoperative period. The expected immunomodulation
is unfortunately failed to be observed.
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